Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additio...
January 15 2021 - 9:21AM
Heidelberg, Germany, January 15, 2021 – Affimed
N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer, today announced the closing of its
previously announced public offering of 16,666,667 common shares,
at the public offering price of $6.00 per share, and the exercise
in full by the underwriters of their option to purchase an
additional 2,500,000 common shares. The exercise of the option to
purchase over-allotment shares brought the total number of common
shares sold by Affimed to 19,166,667 common shares and increased
the gross proceeds raised in the offering, before deducting
underwriting discounts and commissions and estimated expenses of
the offering payable by Affimed, to $115 million.
Jefferies LLC, SVB Leerink LLC and Credit Suisse
Securities (USA) LLC are acting as joint book-running managers and
Laidlaw & Company (UK) Ltd. is acting as co-manager. A shelf
registration statement relating to these securities filed with the
Securities and Exchange Commission (the “SEC”) was declared
effective by the SEC on December 30, 2020. The offering was made
only by means of a prospectus and prospectus supplement. A
prospectus supplement and accompanying prospectus related to the
offering have been filed with the SEC and are available at the
SEC’s website located at www.sec.gov. Copies of the prospectus
supplement and accompanying prospectus related to the offering may
be obtained by contacting Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at (877) 821-7388 or by email at
Prospectus_Department@Jefferies.com, SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525 ext. 6132, or by email at
syndicate@svbleerink.com, or Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, 6933 Louis Stephens Drive,
Morrisville, NC 27560, by telephone at (800) 221-1037, or by email
at usa.prospectus@credit-suisse.com
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat hematologic and solid tumors. The
Company is currently enrolling patients into a
registration-directed study of AFM13 for CD30-positive
relapsed/refractory peripheral T cell lymphoma and into a Phase
1/2a dose escalation/expansion study of AFM24 for the treatment of
advanced EGFR-expressing solid tumors.
Forward-looking Statements
This press release contains statements that
constitute “forward-looking statements,” including with respect to
the proposed offering of common shares and the anticipated use of
the net proceeds. No assurance can be given that the offering
discussed above will be completed on the terms described, or at
all, or that the net proceeds of the offering will be used as
indicated. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the company,
including those set forth in the Risk Factors section of the
company’s registration statement and preliminary prospectus for the
company’s offering filed with the Securities and Exchange
Commission (“SEC”). Copies are available on the SEC’s website,
www.sec.gov. The company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.
Affimed Investor and Media Contact: Alexander
Fudukidis, Head of Investor Relations E-Mail:
a.fudukidis@affimed.com, IR@affimed.com Tel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024